Alan Watt

Company: NodThera Ltd.

Job title: President & Chief Scientific Officer

Seminars:

Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease 9:30 am

Highlighting favorable shifts in cardiovascular biomarkers linked to reduced inflammation-driven cardiometabolic risk Underscoring the role of hypothalamic inflammation as a therapeutic target in obesity Showcasing oral NLRP3 inhibition as a strategy to improve key metabolic parameters in individuals with obesityRead more

day: Conference Day One AM